Terbinafine

Basic Terbinafine Information

• INN (International Nonproprietary Name): Terbinafine
• Brand Names Available In Australia: Lamisil; Terbinex; generics marketed by Mylan, Apotex and other suppliers (brand availability may vary by supplier and pack size).
• ATC Code: D01BA02 — Antifungals For Topical Use (Allylamines), with systemic use for selected indications.

Critical Warnings & Restrictions (Safety First)

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

• Absolute contraindications: known hypersensitivity to terbinafine or any excipients, and chronic or active hepatic disease.
• Before starting oral terbinafine, obtain baseline liver function tests (LFTs) and arrange for ongoing monitoring during systemic courses.
• In older adults, review hepatic and renal function, current medicines (prescription and OTC), and consider fall or occupational risks when counselling about side effects such as dizziness or fatigue.
• Pregnancy: avoid systemic terbinafine where possible; use topical formulations only after a clinician risk–benefit assessment.
• Lactation: oral terbinafine is not recommended; topical therapy may be considered with caution and local clinical advice.

Use this checklist when prescribing or assessing suitability for systemic terbinafine.

• Confirm indication and expected duration (eg. onychomycosis: 250 mg daily for toenails 12 weeks).
• Baseline LFTs and history of liver disease or heavy alcohol use.
• Review concomitant medicines for CYP2D6 interactions and QT‑risk drugs.
• Assess renal function if known impairment; note caution if CrCl <50 ml/min.
• Check pregnancy intent and breastfeeding status.
• Advise patient about common side effects and clear instructions for when to stop and seek medical care.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Terbinafine can cause dizziness, fatigue and occasionally visual disturbance in some people.

Advise patients who experience dizziness, extreme fatigue or blurred vision to avoid driving or operating heavy machinery until symptoms resolve.

Safety‑critical workers and those in regulated roles should be counselled that they may need to disclose medication use to their employer or occupational health service under Australian workplace safety rules.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Usually yes for topical use, or for oral therapy if you feel well.

Avoid driving if you develop dizziness, extreme fatigue, blurred vision or other central nervous system effects, and report such effects promptly to your GP and to the TGA.

Usage Basics

INN, ATC And Brand Names Available In Australia

INN

Terbinafine.

ATC

D01BA02 — Allylamine antifungals for topical use; systemic use is common for nails and scalp infections.

Brand Names

Lamisil is the familiar brand; generics from major manufacturers such as Mylan and Apotex are available.

• Formulations commonly encountered: 250 mg tablets, 1% cream, 1% spray and paediatric granules (weight‑based sachets).
• Topical packs commonly come in 7 g, 15 g and 30 g tubes and 15–30 ml sprays.

Legal Classification (TGA, PBS Context)

• Oral terbinafine (250 mg tablets) is prescription‑only (Rx) under TGA classification.
• Topical 1% formulations are often available OTC in small packs, though larger packs or clinical formulations may require a prescription.
• PBS subsidy status varies by indication and patient eligibility; check current PBS listings and any authority requirements before prescribing for subsidy.
• Pharmacists provide OTC topical advice and dispense prescriptions in line with TGA regulations.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

• Onychomycosis — oral terbinafine 250 mg once daily: fingernails 6 weeks, toenails 12 weeks.
• Tinea corporis/cruris — oral 250 mg once daily for 2–4 weeks.
• Tinea pedis — oral 250 mg once daily for 2–6 weeks.
• Topical cream/spray 1% — apply once or twice daily to the affected area for 1–4 weeks depending on the product and infection site.

Adjustments For Comorbidities

• Children: weight‑based dosing is used (examples: 125 mg <20 kg, 187.5 mg 20–40 kg, 250 mg >40 kg); granules are useful in paediatric practice.
• Hepatic impairment: systemic terbinafine is contraindicated in chronic or active liver disease — do not use oral therapy.
• Renal impairment: exercise caution if CrCl <50 ml/min; consider alternative therapy or specialist advice.
• Elderly: no routine dose reduction but monitor hepatic and renal function and review concomitant medicines.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember, unless it is close to the next scheduled dose.

Do not double dose to make up for a missed tablet.

For topical therapy, continue regular application and complete the full course even if symptoms improve.

Document missed doses in clinical notes for long systemic courses and reinforce adherence at each review.

Interaction Chart

Food And Drinks (Alcohol, Australian Diet Context)

There is no direct acute interaction between alcohol and terbinafine, but both can place stress on the liver.

Advise minimising alcohol during oral treatment and while monitoring LFTs, particularly for patients with high alcohol intake or existing liver risk factors.

Common Drug Conflicts

Terbinafine is a moderate inhibitor of CYP2D6 and can interact with drugs metabolised by this pathway.

Exercise caution with medicines that are CYP2D6 substrates (for example some SSRIs, tricyclic antidepressants and certain beta‑blockers).

• High‑risk classes: certain antidepressants, antiarrhythmics, some antipsychotics and drugs with heavy hepatic metabolism.
• Always use an electronic interaction checker in the pharmacy or hospital system for comprehensive, patient‑specific checks.
• Consult a specialist or clinical pharmacist for complex polypharmacy cases.

User Reports & Trends (Australian Patient Experience)

• Positive themes: rapid symptomatic relief with topical terbinafine for tinea corporis and tinea pedis, and helpful pharmacist guidance in retail chains and independents.
• Negative themes: oral therapy for nails requires patience; common oral complaints include taste disturbance and gastrointestinal upset.
• Safety concern theme: many patients express worry about liver effects and seek GP follow‑up and LFT monitoring.

Anecdotal reports complement clinical evidence but should be balanced with formal adverse event reporting to the TGA.

Access & Purchase Options

National Chains And Community Pharmacies

Major Australian retail pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart stock topical terbinafine OTC and provide patient counselling.

Oral tablets require a prescription, and these chains offer prescription dispensing and follow‑up services.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth can be used to obtain prescriptions for oral terbinafine where clinically appropriate, and accredited online pharmacies and e‑prescription systems are legitimate supply routes.

Rural patients commonly use mail‑order pharmacy services for access to both topical and prescription formulations.

In our online pharmacy, terbinafine is available without a prescription, with discreet delivery to Australia in 9–21 days.

Avoid importing prescription drugs from unregulated overseas sites due to safety and regulatory risks.

Checklist For Safe Purchase:

• Verify TGA registration of the product and supplier.
• Ask to speak with a pharmacist for counselling before purchase.
• Confirm PBS subsidy and authority requirements if seeking subsidised supply.
• Prefer accredited Australian online pharmacies and check contact details and pharmacist availability.

Mechanism & Pharmacology

Simplified Explanation

Mechanism

Terbinafine inhibits squalene epoxidase in fungi, depleting ergosterol and causing accumulation of toxic squalene, which is fungicidal.

Pharmacokinetics

Oral terbinafine is well absorbed and concentrates in keratinous tissues such as nails and skin, accounting for its efficacy in onychomycosis.

Spectrum

Active against dermatophytes commonly causing tinea and nail infections; topical forms have minimal systemic absorption.

Indications & Off‑Label Uses

TGA‑Approved And Standard Indications

• Onychomycosis (nail infections).
• Tinea pedis (athlete’s foot).
• Tinea cruris (jock itch).
• Tinea corporis (ringworm).
• Tinea capitis (scalp ringworm), particularly in paediatrics.

Off‑Label And Special Situations

• Occasional off‑label use includes some cutaneous candidiasis and mixed fungal infections where alternative therapies are unsuitable.
• Systemic therapy is reserved for recalcitrant, extensive, or nail/scalp disease where topical therapy is insufficient.
• When prescribing off‑label, document the rationale, discuss risks and benefits, and obtain informed consent.

Key Clinical Findings (Recent Evidence Summary)

• Systemic terbinafine achieves higher mycological cure rates for onychomycosis compared with many oral azoles in multiple trials and remains a standard first‑line systemic option for nail disease.
• Topical terbinafine is effective for uncomplicated tinea corporis/cruris/pedis and carries far fewer systemic risks than oral therapy.
• Despite low incidence, hepatotoxicity is a well‑recognised serious risk with systemic terbinafine; baseline and on‑treatment LFT monitoring remains standard clinical practice.
• Pulse and combination regimens are discussed in the literature but evidence is mixed; standard daily 250 mg dosing for recommended durations remains guideline‑preferred in many settings.

Clinicians should consult up‑to‑date local guidelines and recent reviews for the latest 2025–2026 data and specific patient management algorithms.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros/Cons Checklist For Counselling:

• Efficacy: terbinafine is highly effective for nails; topical azoles work well for superficial tinea.
• Hepatotoxicity: systemic options require LFT monitoring.
• Drug interactions: azoles have significant CYP interactions; terbinafine mainly affects CYP2D6.
• Pregnancy/lactation: many systemic agents are unsuitable; topical agents are preferred where possible.
• Cost/PBS: discuss generics and subsidy eligibility with the patient.

Common Questions (Pharmacy Consultation FAQs)

• How long until I see improvement? Topical therapy may relieve symptoms in days to weeks; oral treatment for nails requires months for visible improvement because nails grow slowly.
• Do I need blood tests? Baseline LFTs and as‑needed monitoring are recommended for systemic therapy.
• Can I use topical and oral together? Sometimes they are used concurrently for severe or extensive infections — coordinate with the prescriber.
• Is it safe for children? Paediatric granules and weight‑based dosing are used for tinea capitis; specialist or paediatric guidance is advised.
• When to return to the GP? Return if symptoms worsen, a new rash develops, or if signs of liver injury (eg. jaundice, dark urine, severe abdominal pain) or severe GI/CNS effects appear.

Micro‑FAQ: Can I stop treatment early if symptoms improve?

No. For nail infections particularly, stopping early risks relapse; complete the full recommended course even if visible improvement is slow.

Price & Access Comparison Table

Summary & Typical Price Ranges (AUD)

Topical 1% cream or spray: approximately AUD $8–30 for OTC packs.

Oral terbinafine (private script): approximately AUD $30–150 per pack depending on brand and pack size; PBS‑subsidised cost is lower for eligible patients.

Access Checklist — Major Chains Vs Rural Availability

• Confirm whether a prescription or PBS authority is required for subsidised supply.
• Ask your pharmacist about available generics to reduce cost.
• Consider mail‑order supply for remote or rural patients; check delivery times and dispensing rules.
• Verify the supplier is TGA‑registered and supplies genuine product.

Registration & Regulation

TGA Approval And Pharmacovigilance

• Terbinafine formulations are TGA‑registered; oral forms are prescription‑only in Australia.
• Suspected adverse reactions, especially hepatic events, should be reported to the TGA Adverse Event Management System.
• Maintain appropriate dispensing and patient records as required by national guidance.

PBS Subsidy Details

• PBS listings and authority requirements change periodically; verify current PBS criteria on the PBS website before prescribing for subsidy.
• Onychomycosis prescriptions often require authority approval for PBS subsidy.

Storage & Handling

Household Storage In Australian Climate

Store terbinafine products at 15–30°C and protect from moisture and direct sunlight.

Avoid storing topical tubes in humid bathrooms where possible and keep containers sealed between uses.

Do not freeze topical products.

Cold‑Chain And Pharmacy Handling

• No refrigerated storage is required for terbinafine formulations.
• Pharmacies should store stock within recommended temperature ranges and rotate stock to manage expiry.
• Provide patients with a leaflet on proper disposal of unused medicine and empty tubes.

Guidelines For Proper Use (Pharmacist Counselling Style)

Key Counselling Points (Patient‑Facing)

• Explain the indication and expected treatment duration (for example, 12 weeks for toenail onychomycosis with oral terbinafine 250 mg daily).
• Advise the need for baseline LFTs for systemic therapy and symptoms of hepatotoxicity to watch for: dark urine, yellowing of the skin/eyes, severe abdominal pain.
• Describe common side effects: taste disturbance, gastrointestinal upset and headache with oral therapy; mild local irritation with topical use.
• Reinforce adherence: nail infections require the full course despite slow visible improvement.
• Advise minimising alcohol intake while on oral terbinafine and during monitoring.

Patient Advice From PBS And National Health Authorities

Direct patients to official resources such as the TGA and PBS for up‑to‑date regulatory and subsidy information.

For rural and remote patients, discuss telehealth and mail‑order options to maintain continuity of care and follow‑up.

Short Template Script For Pharmacists:

• “This medicine is for your fungal infection; take one 250 mg tablet daily for X weeks (or apply the cream once or twice daily to the affected area).”
• “We will arrange a baseline blood test for your liver function if you are taking the tablets, and please contact your GP or emergency services if you notice jaundice, dark urine or severe abdominal pain.”
• “Avoid excessive alcohol while on tablets and return for follow‑up if symptoms do not improve or if side effects occur.”

Delivery Across Australia